contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


combining-evp-roles-of-human-health-biosolutions-and-strategy-and-integration

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Novonesis är verksamma inom biokemi. Bolaget utvecklar enzymer och mikroorganismer för industriellt bruk. Enzymerna är ett protein som används inom ett flertal olika branscher, huvudsakligen inom jordbruks- och livsmedelsindustrin. Produkterna används inom livsmedel samt kläder, och försäljning innehas på global nivå, med störst närvaro inom Norden och Europa. Bolaget har sitt huvudkontor i Bagsværd.

Novonesis

As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. COPENHAGEN, Denmark – After successfully combining into one...

As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy &amp; Integration.&nbsp; COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy &amp; Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vice President for Strategy &amp; Integration, will step into the newly combined role as EVP Human Health Biosolutions &amp; Strategy. Amy Byrick steps down as EVP for Human Health Biosolutions. The change to the Executive Leadership team will be effective no later than August 1, 2025.&nbsp; “Since combining into Novonesis in January 2024, we have made impressive progress in coming together as one company while delivering on our synergy targets. Throughout this integration journey, Henrik has orchestrated and driven the transformation and overall integration. Henrik’s strong strategic and business acumen, coupled with his background spanning R&amp;D and commercial leadership within pharmaceuticals, nutrition and health, make him an excellent profile to further develop Novonesis’ Human Health business and ensure we continue to successfully execute on our strategy,” says Ester Baiget, CEO, Novonesis. Amy Byrick will open a new chapter in her life and pursue a non-Executive career. She will therefore step down from her position as Executive Vice President of Human Health Biosolutions and leave the company by July 31. Amy joined Novozymes’ Executive Leadership Team in 2021 as EVP of Strategy &amp; Transformation, and she was appointed Executive Vice President of Human Health Biosolutions in Novonesis in 2023.&nbsp; “I want to extend a heartful thank you to Amy for her extraordinary contribution and commitment to creating Novonesis and establishing our Human Health Biosolutions Business. Amy has been a key player in driving the combination of Novozymes and Chr. Hansen, and she has also been instrumental in ensuring that Novonesis is well-positioned to meet the evolving nutritional and health needs of a growing population. I send my warmest wishes to Amy as she embarks on this new chapter in her life,” says Ester Baiget.&nbsp; Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/f54b123d-4b34-450d-9a5e-a6bf4211d400">2025_Combining_EVP_roles</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA5NzQ5NSM0MDIxNDQwMTkjMjAwMjM5NA==" alt=""> <img src="https://ml-eu.globenewswire.com/media/MmE1NWQyNGYtZWM2YS00ZGMzLTgzYjctY2Y1MDQzMDQzNzdmLTEwMTM5NjctMjAyNS0wNS0xOS1lbg==/tiny/Novonesis-Novozymes-A-S-.png" alt="">